What Happened?
Calgary, AB-based Providence Therapeutics Appointed Robert Georgantas as President and Chief Technology Officer
About the Company
Providence is a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with a focus on infectious diseases and oncology. Initially founded as a cancer vaccines company in 2015, in response to a worldwide need for a COVID-19 vaccine, Providence expanded its focus beyond oncology therapies to develop an mRNA vaccine for COVID-19. Providence works with multiple industry collaborators, universities, nongovernmental agencies and multiple arms of the Government of Canada to discover and develop vaccines and treatments for infectious diseases and cancer. This has resulted in the development of an mRNA vaccine platform that includes a proprietary design algorithm and proprietary, scalable manufacturing processes.
About the Person
Robert Georgantas is President and Chief Technology Officer at Providence Therapeutics. Previously, Robert held various senior IT leadership roles in the industry.
Info Source
News
Short Profile